Quanterix (QTRX) Stock Rating Lowered by Zacks Investment Research

Share on StockTwits

Quanterix (NASDAQ:QTRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday.

According to Zacks, “Quanterix Corporation is a developer of tools in high definition diagnostics. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. It offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa Buffers and Disposable Tips. The company services include Simoa Accelerator Lab and custom assay development services. Quanterix Corporation is based in LEXINGTON, United States. “

Several other analysts have also recently weighed in on QTRX. ValuEngine upgraded shares of Quanterix from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. BTIG Research reiterated a “buy” rating and issued a $26.00 price target on shares of Quanterix in a report on Sunday, May 13th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $26.50.

Shares of Quanterix stock opened at $14.08 on Wednesday. Quanterix has a 52-week low of $14.00 and a 52-week high of $24.81.

Quanterix (NASDAQ:QTRX) last issued its earnings results on Wednesday, May 9th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.08). sell-side analysts expect that Quanterix will post -1.12 EPS for the current year.

In related news, SVP Ernest Orticerio sold 25,000 shares of Quanterix stock in a transaction on Tuesday, June 5th. The shares were sold at an average price of $17.15, for a total value of $428,750.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 31.60% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Flagship Pioneering Inc. bought a new stake in Quanterix in the fourth quarter valued at $43,595,000. Platinum Investment Management Ltd. bought a new stake in Quanterix in the fourth quarter valued at $3,757,000. Perceptive Advisors LLC bought a new stake in Quanterix in the fourth quarter valued at $3,637,000. Landscape Capital Management L.L.C. bought a new stake in Quanterix in the fourth quarter valued at $720,000. Finally, Goldman Sachs Group Inc. bought a new stake in Quanterix in the fourth quarter valued at $873,000. Institutional investors and hedge funds own 45.71% of the company’s stock.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer.

Get a free copy of the Zacks research report on Quanterix (QTRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply